BioMarin Pharmaceutical Inc. ($BMRN) Stock Forecast: Up 5.1% Today

What is BioMarin Pharmaceutical Inc.?

BioMarin Pharmaceutical (BMRN): BioMarin Pharmaceutical, a biotechnology company specializing in rare genetic disease therapies, saw a significant uptick in its stock performance today.

Why is BioMarin Pharmaceutical Inc. going up?

BMRN stock is up 5.1% on May 29, 2026 15:11

• BMRN's stock surged on favorable Phase 3 results for its medication Voxzogo, designed to treat children with hypochondroplasia a rare genetic disorder affecting bone growth.
• The successful meeting of the primary trial goal for Voxzogo, which displayed a noteworthy rise in annualized growth velocity in patients, has instilled confidence and optimism among investors regarding the company's future.
• Analysts have adjusted their fair value projection for BMRN, underscoring the potential benefits of the forthcoming Amicus acquisition, growth avenues for Voxzogo, and overall pipeline advancements, while acknowledging worries about competitive forces and recent trial halts.
• The encouraging Voxzogo study outcome not only affirms the drug's effectiveness but also underscores BioMarin's dedication to addressing medical needs, leading to the positive market movement of its stock.

BMRN Price Chart

BMRN Technical Analysis

BMRN News

BMRN: Revenue Guidance Revision Will Reveal New Competitive Dynamics Ahead

AnalystConsensusTarget has updated its fair value estimate for BioMarin Pharmaceutical (BMRN) to $89.96, reflecting revised assumptions on various financial metrics and a blend of recent analyst price target adjustments. The company's future is influenced by the planned Amicus acquisition, potential Voxzogo indication expansions, and pipeline developments, all while navigating competitive pressures and recent trial discontinuations. There's a divide among analysts, with some highlighting growth opportunities and others expressing caution regarding Voxzogo's long-term prospects amidst rising competition.

https://simplywall.st/narratives/lfwega1e-bmrn-revenue-guidance-revision-will-reveal-new-competitive-dynamics-ahead?bpId=4599143&link_type=cta_narrative_prompt_after_quote

BioMarin's Voxzogo meets goal in late-stage study for hypochondroplasia

BioMarin Pharmaceutical Inc.'s drug Voxzogo successfully met its primary endpoint in a late-stage clinical trial for children with hypochondroplasia, a genetic disorder affecting bone growth. The study found that children treated with Voxzogo experienced a significant increase in annualized growth velocity compared to those receiving a placebo. This positive outcome could lead to a new treatment option for this rare condition.

https://www.msn.com/en-us/health/other/biomarins-voxzogo-meets-goal-in-late-stage-study-for-hypochondroplasia/ar-AA23Lhi4

BioMarin: Positive Phase 3 Data for Voxzogo in Hypochondroplasia; Shares Very Undervalued

BioMarin has reported positive Phase 3 data for its drug Voxzogo in treating children with hypochondroplasia, a rare short-stature condition. The study successfully met its primary endpoint, showing that patients treated with Voxzogo grew 2.33 centimeters per year faster than the placebo group and exhibited significant improvements in arm span. Following this announcement, BioMarin's shares increased by nearly 8%.

https://www.morningstar.com/company-reports/1483067-biomarin-positive-phase-3-data-for-voxzogo-in-hypochondroplasia-shares-very-undervalued

Trending Today

Rivian Automotive Inc. ($RIVN) Stock Forecast: Up 5.1% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 8.7% Today

Wix.com Ltd. ($WIX) Stock Forecast: Up 5.3% Today

Autodesk Inc. ($ADSK) Stock Forecast: Down 5.0% Today

ServiceNow Inc. ($NOW) Stock Forecast: Up 14.8% Today

Palantir Technologies Inc ($PLTR) Stock Forecast: Up 12.4% Today

Transdigm Group Incorporated Inc. ($TDG) Stock Forecast: Up 0.6% Today

Capri Holdings Limited ($CPRI) Stock Forecast: Down 5.6% Today

ONEOK Inc. ($OKE) Stock Forecast: Down 5.2% Today

Xerox Corporation ($XRX) Stock Forecast: Up 5.4% Today

BioMarin Pharmaceutical Inc. Price History

13.00.2026 - BMRN Stock was down 5.1%

• The announcement of BioMarin Pharmaceutical's estimated 2025 revenue of $3.2 billion and the strong performance of Voxzogo at $920 million at the recent conference should have been positive news. However, the market may have reacted negatively due to concerns about the company's ability to meet these revenue targets.
• The hiring of Arpit Davé as Chief Digital and Information Officer to accelerate rare disease therapies shows the company's commitment to innovation. However, the market might have interpreted this move as a signal of potential challenges in the current R&D and commercial operations that require urgent attention.
• Despite the outlined growth strategy, pipeline progress, and Amicus integration positioning BioMarin for sustained double-digit compound annual growth rate, investors may have focused on the weak long-term outlook highlighted in the tactical trading analysis. This could have contributed to the bearish movement in the stock.
• The absence of clear long-term support signals and elevated downside risk might have spooked investors, leading to a sell-off of the stock despite the positive developments and revenue projections.

19.11.2025 - BMRN Stock was up 7.7%

• The appointment of Rashmi Ramchandani as the new chief accounting officer brings fresh leadership to BioMarin, potentially signaling positive changes within the company.
• Despite concerns about cost-cutting measures and pipeline shifts, investors seem optimistic about BioMarin's future growth prospects, particularly with the Inozyme acquisition and the focus on rare disease treatments.
• The selling of shares by Hudson Bay Capital Management LP and Bellevue Group AG may have initially raised some eyebrows, but the increased holdings by other institutional investors like Dodge & Cox and Viking Global suggest confidence in BioMarin's long-term potential.
• Overall, the market's bullish response to BioMarin today could be attributed to a combination of new leadership, strategic acquisitions, and investor confidence in the company's ability to navigate through its current transformation phase successfully.

21.04.2026 - BMRN Stock was up 6.6%

• The bullish movement in BMRN stock can be attributed to the positive Phase 3 pivotal study results for VOXZOGO in children with hypochondroplasia. Meeting its primary endpoint with significant improvements in annualized growth velocity and other key measures has generated positive investor sentiment.
• Despite the mixed outcomes from the Phase 1/2 study of BMN 351 for Duchenne muscular dystrophy, which led to a decline in stock price, the company's decision to continue with the higher dose in future trials could have provided some reassurance to investors.
• The overall positive sentiment surrounding BioMarin's successful trials and potential new drug applications has likely overshadowed concerns raised in the SWOT analysis, contributing to the bullish movement in the stock today.

21.04.2026 - BMRN Stock was up 5.1%

• Positive Phase 3 pivotal study results for VOXZOGO in children with hypochondroplasia, demonstrating significant improvements in growth velocity and other key metrics, fueled investor optimism and drove the bullish movement.
• BioMarin's plans to submit a supplemental New Drug Application to regulatory authorities in the near future added to the positive sentiment surrounding the stock.
• Despite facing competitive headwinds and setbacks in other clinical studies, the successful results from the VOXZOGO trial overshadowed these concerns and contributed to the stock's surge.
• Analyst downgrades and uncertainties mentioned in the SWOT analysis did not seem to impact the market movement significantly, as the positive trial data took the spotlight and drove the stock price higher.

29.04.2026 - BMRN Stock was up 5.1%

• BMRN's stock surged on favorable Phase 3 results for its medication Voxzogo, designed to treat children with hypochondroplasia a rare genetic disorder affecting bone growth.
• The successful meeting of the primary trial goal for Voxzogo, which displayed a noteworthy rise in annualized growth velocity in patients, has instilled confidence and optimism among investors regarding the company's future.
• Analysts have adjusted their fair value projection for BMRN, underscoring the potential benefits of the forthcoming Amicus acquisition, growth avenues for Voxzogo, and overall pipeline advancements, while acknowledging worries about competitive forces and recent trial halts.
• The encouraging Voxzogo study outcome not only affirms the drug's effectiveness but also underscores BioMarin's dedication to addressing medical needs, leading to the positive market movement of its stock.

24.01.2026 - BMRN Stock was down 5.5%

• BioMarin posted strong Q4 revenue surpassing forecasts and a positive full-year 2025 performance. However, the stock witnessed a bearish trend possibly due to falling short of analyst predictions on non-GAAP EPS and adjusted EBITDA.
• The FDA's rejection of BioMarin's gene therapy for hemophilia A, delaying its potential market launch, might have impacted the negative investor sentiment on the company's future revenue prospects.
• An AI analysis indicating a bleak long-term outlook and increased downside risk for BioMarin could have also influenced the downward pressure on the stock.
• In conclusion, the combination of financial performance lagging expectations and regulatory obstacles could have contributed to the bearish movement of BioMarin's stock today.

18.02.2026 - BMRN Stock was down 5.4%

• The halt of mid-stage trials for the bone disorder treatment, Voxzogo, due to safety concerns like hip joint slippage in patients, led to a 4% drop in BioMarin's shares.
• The discontinuation of dosing and enrollment in Phase 2 trials for Voxzogo targeting various disorders due to slipped capital femoral epiphysis (SCFE) events introduced uncertainty and negatively impacted the stock.
• The competition in the achondroplasia indication, with the FDA approval of Ascendis Pharma's Yuviwel, added pressure on BioMarin as it halted studies for certain disorders, affecting investor confidence and contributing to the bearish movement.
• Despite being considered a compelling value investment opportunity with strong financial health and profitability metrics, the negative developments in the Voxzogo trials overshadowed the potential growth prospects, resulting in the stock's decline.

19.01.2026 - BMRN Stock was up 5.1%

• BioMarin's bullish movement today can be attributed to the positive sentiment surrounding the company, as highlighted by analysts and institutional investors increasing their stakes in the company.
• The upcoming conference call to discuss the fourth quarter and full-year 2025 financial results likely generated optimism among investors about the company's performance and future prospects.
• The continued interest from institutional investors, such as Aberdeen Group plc reducing its stake and New York Life Investment Management LLC making a new investment, indicates confidence in BioMarin's long-term growth potential.
• LSV Asset Management's significant increase in stake further reinforces the positive outlook on BioMarin, contributing to the bullish momentum in the stock price.

27.01.2026 - BMRN Stock was up 5.2%

• Concerns may have initially arisen from the EVP's stock sale, but investors did not seem discouraged by this insider activity.
• The decision to halt the hemophilia gene therapy, Roctavian, due to underwhelming sales could have been seen as a strategic choice to minimize losses and focus on more promising ventures.
• BioMarin's increased efforts in business development amidst rising competition for Voxzogo could have raised investors' optimism about the company's ability to navigate challenges and stay competitive.
• Participation in upcoming investor conferences and a positive Q4 earnings report, surpassing expectations in both earnings and revenue, likely played a role in boosting the positive sentiment surrounding BioMarin's stock today.

10.01.2026 - BMRN Stock was up 5.0%

• BMRN saw an upward trend today following positive analyst ratings and price target increases from various firms, including Piper Sandler, Barclays, and Canaccord Genuity.
• Factors such as the impending acquisition of Amicus Therapeutics and the upcoming data release for its experimental therapy INZ-701 have contributed to the positive outlook surrounding BMRN.
• Analysts view BMRN as undervalued with significant growth potential, anticipating revenue escalation and profit margin enhancement in the coming years.
• The company's strategic acquisitions and dedication to rare disease treatments have bolstered investor confidence, driving the bullish market performance.

12.01.2026 - BMRN Stock was up 1.1%

• Despite anticipated Q4 earnings decline, BioMarin Pharmaceutical (BMRN) saw an upward trend, reflecting investor confidence in its long-term prospects.
• Favorable ratings from analysts, adjustments in price targets, and excitement surrounding the impending acquisition of Amicus Therapeutics have contributed to the positive outlook for BMRN.
• The upcoming crucial data release for the experimental therapy INZ-701, designed for treating ENPP1 Deficiency, stands as a significant driver for BioMarin's presence in the rare disease market and likely heightened investor confidence.
• The generally optimistic sentiment towards BMRN, supported by promising forecasts, analyst support, and forthcoming catalysts, has outweighed worries about the projected earnings decline for the quarter.

05.04.2026 - BMRN Stock was up 0.8%

• BioMarin Pharmaceutical (BMRN) experienced a strong bullish movement today following the release of its Q1 2026 earnings report and conference call.
• The company reported Q1 revenues of $766 million and raised its full-year revenue guidance, driven by the acquisition of Amicus and strong performance of key therapies.
• Despite falling short of analyst expectations on adjusted EPS for Q1, the market reacted positively to the increased revenue outlook and strategic acquisitions.
• The presentation of new data on the efficacy of Voxzogo in treating achondroplasia also contributed to the positive sentiment surrounding BioMarin Pharmaceutical, showcasing the company's commitment to advancing treatments for rare diseases.